Form 4: Immunovant CFO Sells Shares to Cover Tax Obligations After RSU Vesting
SEC Form 4 Filing
Immunovant's Chief Financial Officer, Eva Renee Barnett, sold 4,174 shares of common stock to cover tax obligations following the vesting of restricted stock units.
Summary
- Eva Renee Barnett, the Chief Financial Officer of Immunovant, Inc., sold 4,174 shares of common stock on November 20, 2024.
- The sale was executed at a weighted average price of $25.45 per share, with individual transactions ranging from $24.91 to $25.81.
- This transaction was not a discretionary sale but was mandated by Immunovant to cover tax withholding obligations related to the vesting of 7,051 restricted stock units (RSUs).
- The RSUs were part of a grant of 112,816 RSUs awarded on August 17, 2022, with 7,051 vesting on November 17, 2024.
- Following the sale, Barnett directly owns 331,169 shares of Immunovant common stock.
Sentiment
Score: 5
Explanation: The document reflects a routine transaction related to executive compensation and tax obligations. It does not indicate any positive or negative sentiment regarding the company's performance or future prospects.
Industry Context
This is a routine transaction for executives who receive stock-based compensation. It is common for companies to mandate 'sell to cover' transactions to manage tax obligations for employees.
Comparison to Industry Standards
- The 'sell to cover' method for handling tax obligations on vesting RSUs is a standard practice across many publicly traded companies.
- Executive stock sales are common and are often disclosed via SEC Form 4 filings, which are standard for reporting insider transactions.
- The price range of $24.91 to $25.81 per share is within the typical trading range for Immunovant stock at the time of the transaction.
Stakeholder Impact
- The sale of shares by the CFO has a minimal impact on shareholders as it is a routine transaction to cover tax obligations.
- The transaction does not impact employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 08/17/2022 | Date of the original grant of 112,816 restricted stock units (RSUs). |
| 11/17/2024 | Date when 7,051 of the RSUs vested. |
| 11/20/2024 | Date of the sale of 4,174 shares of common stock. |
| 11/22/2024 | Date the Form 4 was signed. |
Keywords
Immunovant, stock sale, Form 4, Eva Renee Barnett, RSU, tax obligations, executive transaction, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.